About Crescendo Biologics
Crescendo Biologics is a Healthcare company based in Cambridge (United Kingdom) founded in 2009. Crescendo Biologics is focused on T cell enhancing therapeutics. It operates on a HealthTech model. Crescendo Biologics has raised $140.96 million across 7 funding rounds from investors including BioNTech, Takeda Pharmaceuticals and HHS. The company has 60 employees. Its chief executive, as recorded, is Theodora Harold. Crescendo Biologics offers products and services including Humabody® CB307, ZL-1102 (Humabody® CB001), and CB699. Its focus areas include Biotechnology and Immuno-Oncology. Its legal entity is Crescendo Biologics Limited.
Company details
Crescendo Biologics is engaged in the development of novel T cell enhancing therapeutics, primarily in the field of immuno-oncology. The company is known for its proprietary Humabody VH platform, which is utilized to create bispecific and multispecific biologics. Solutions such as CB307 and ZL-1102 are being developed for various medical conditions including cancer and psoriasis. The company collaborates strategically with global partners to advance clinical trials and expand therapeutic applications within the healthcare sector.
- Headquarters Cambridge, United Kingdom
- Employees 60
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Email••••••••
- Website crescendobiologics.com
- Social LinkedIn X
- Legal Name Crescendo Biologics Limited
- Annual Revenue$6.76 M (USD)-15as on Dec 31, 2021
- Net Profit-$7.71 M (USD)19as on Dec 31, 2021
- EBITDA-$10.32 M (USD)19as on Dec 31, 2021
- Total Equity Funding$140.96M (USD)
in 7 rounds
- Latest Funding Round$32M (USD), Series B
Jul 2023
- InvestorsBioNTech
& 13 more
- Employee Count60
Products & Services of Crescendo Biologics
Crescendo Biologics offers a comprehensive portfolio of products and services, including Humabody® CB307, ZL-1102 (Humabody® CB001), and CB699.
A bispecific therapeutic for immuno-oncology is being developed.
A topical treatment for psoriasis is under evaluation.
An immune cell engager for oncology is presented.
Funding Insights of Crescendo Biologics
Crescendo Biologics has successfully raised a total of $140.96M across 7 strategic funding rounds. The most recent funding activity was a Series B round of $32 million completed in July 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $140.96M
- Total Rounds 7
- Last Round Series B — $32M
- First Round $147,000
(Jun 2009)
- Investors Count 14
All 7 funding rounds of Crescendo Biologics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul 2023 | $32M | Series B | – | Takeda, Kreos Capital | |
| Apr 2018 | $70M | Series B | – | Andera Partners | |
| Dec 2014 | Series B | – | – | ||
| Apr 2014 | $3.3M | Series A | – | – | |
| Dec 2013 | $28.54M | Series A | – | Imperial Innovations | |
| Oct 2009 | $7.12M | Seed | – | Sofinnova Partners | |
| Jun 2009 | $147,000 | Grant | – | – |
14 investors in total: 14 institutional.
Investors in Crescendo Biologics
Crescendo Biologics has secured backing from 14 investors, including venture fund and institutional investors. Prominent investors backing the company include BioNTech, Takeda Pharmaceuticals and HHS.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Sofinnova Partners is focused on life sciences and healthcare investments. | sofinnovapartners.com | Paris, France | ||
Capital is provided to firms for growth, buyouts, and acquisitions. | 2001 | anderapartners.com | Paris, France | |
Investments are directed toward early and growth stage companies. | quancapital.com | Pudong, China | ||
Venture debt is provided to growth-stage companies across multiple sectors. | 1998 | kreoscapital.com | London, United Kingdom | |
Venture capital and advisory services are offered across multiple sectors. | 2001 | ipgroupplc.com | London, United Kingdom | |
| takedaventures.com | ||||
Life science companies are supported through strategic investments. | embl-ventures.com | Heidelberg, Germany | ||
| astellasventure.com | ||||
Investments in startups are focused on Europe and the US. | 1986 | imperialinnovations.co.uk | London, United Kingdom | |
| avlar.com |
Investor details for Crescendo Biologics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Crescendo Biologics
27 people are tracked at Crescendo Biologics (13 in leadership, 11 in board & advisors, 3 in team); the tracked headcount is 60.
| Name | Role | Group |
|---|---|---|
Theodora Harold | CEO | Leadership |
Kevin Stuart Johnson | Chairman | Leadership |
Amanda Jane Bettison | Ex-Secretary | Leadership |
Clive James Dix | Ex-Director | Leadership |
Igor Matushansky | Non-executive Director | Leadership |
David Brown | Director | Leadership |
Brenda Elizabeth Reynolds | secretary | Leadership |
Eva lotta Coulter | Non-executive director | Leadership |
Michael John Owen Wakelam | Ex-Director | Leadership |
Alan Gilbert Goodman | Ex-Director | Leadership |
Colette Johnston | VP, Discovery | Leadership |
Laurie Galson-Holt | Associate Director, Business Development & IP | Leadership |
Julia Pizzey | Director, CMC Analytical Development | Leadership |
Hardev Pandha | Advisor | Board & advisors |
Kevin Johnson | Chairman | Board & advisors |
Marietta Wu | Non-Executive Director | Board & advisors |
Kerry Fisher | Advisor | Board & advisors |
Gilles Nobécourt | Non-Executive Director | Board & advisors |
Larry Fong | Scientific Advisor | Board & advisors |
Graziano Seghezzi | Non-Executive Director | Board & advisors |
7 more people are available in the full profile.
Complete people profiles for Crescendo Biologics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Crescendo Biologics
3 dated milestones of Crescendo Biologics across 14 years, from founding to its latest funding, stage changes and deals.
- Founded Crescendo Biologics is founded.
- Funding First funding round of $147K.
- Funding Latest funding round, Series B, of $32.0M.
Web traffic of Crescendo Biologics
Websites that share an audience with Crescendo Biologics (crescendobiologics.com).
- Global rank#13,705,548
among all websites
- Category rank#8,482
Health · Biotechnology and Pharmaceuticals
- Bounce rate45%
- Pages per visit1.1
- DevicesDesktop 20% · Mobile 80%
Websites whose visitors overlap most with Crescendo Biologics. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| cosmobio.co.jp | 100% | 130.8K | View details | ||
paris-biotech.com | paris-biotech.com | 100% | – | ||
antibodysociety.org | antibodysociety.org | 100% | #1,462,344 | – | |
mrctechnology.org | mrctechnology.org | 69% | – | ||
affitech.com | affitech.com | 63% | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Crescendo Biologics
Complete news archive for Crescendo Biologics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Crescendo Biologics
Crescendo Biologics was founded in 2009.
Crescendo Biologics is headquartered in Cambridge, United Kingdom. It is registered at Cambridge, Cambridgeshire, United Kingdom.
Theodora Harold is the CEO of Crescendo Biologics, as recorded in our data.
Crescendo Biologics is a funded company, having raised a total of $140.96M across 7 funding rounds to date. The company's 1st funding round was a Grant of $147K, raised on Jun 2009.
Crescendo Biologics has 60 employees.
Annual revenue of Crescendo Biologics is $6.76M as on Dec 31, 2021.
Crescendo Biologics is engaged in the development of novel T cell enhancing therapeutics, primarily in the field of immuno-oncology. The company is known for its proprietary Humabody VH platform, which is utilized to create bispecific and multispecific biologics. Solutions such as CB307 and ZL-1102 are being developed for various medical conditions including cancer and psoriasis. The company collaborates strategically with global partners to advance clinical trials and expand therapeutic applications within the healthcare sector.
Crescendo Biologics offers Humabody® CB307, ZL-1102 (Humabody® CB001), and CB699.
Crescendo Biologics has 14 investors. Key investors include BioNTech, Takeda Pharmaceuticals, HHS, IP Group, and Kreos Capital.
Crescendo Biologics operates through Crescendo Biologics Limited.